Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
226-240 of 4721 results
Gilead Sciences completes acquisition of Kite Pharma
Gilead Sciences has announced the completion of the previously announced transaction for Dodgers Merger Sub a wholly-owned subsidiary of Gilead (purchaser), to acquire Kite Pharma, for $180 per share, net to the seller in cash, without interest, or approximately $11.9bn in the aggregate.
Drug Research > Drug Discovery & Development > News
US HHS accelerates development of first Ebola vaccines and drugs
The US Department of Health & Human Services (HHS) has accelerated the development of first Ebola vaccines and drugs.
Drug Research > Drug Discovery & Development > News
Novartis, UC Berkeley collaborate to tackle undruggable disease targets
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered undruggable.
Drug Research > Drug Discovery & Development > News
Evotec buys stake in Exscientia to advance AI-based drug discovery
By PBR Staff Writer
Germany-based Evotec has acquired a minority stake worth €15m in Exscientia to advance the British company’s artificial intelligence (AI)-driven drug discovery.
Drug Research > Drug Discovery & Development > News
Jacobs secures contract from Ferring Pharmaceuticals for research and development headquarters in Copenhagen
Jacobs Engineering Group received an engineering, procurement, construction management and validation (EPCmV) services contract for the new Ferring Pharmaceuticals research and development (R&D) headquarters, which will be located in Copenhagen, Denmark.
Drug Research > Drug Discovery & Development > News
Autolus secures $80m series C funding
Autolus, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, announced that it closed on a $80m (£59m) series C financing.
Drug Research > Drug Discovery & Development > News
SalvaRx, Immunova establish new JV firm Saugatuck Therapeutics
By PBR Staff Writer
SalvaRx has signed an agreement with Immunova to create a new joint venture (JV) firm Saugatuck Therapeutics.
Drug Research > Drug Discovery & Development > News
Landos Biopharma raises $10m in series A financing
Landos Biopharma, an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced that it has raised $10m in a series A financing led by life sciences investment management firm Perceptive Advisors, which will serve as its exclusive investor for the Series A round.
Drug Research > Drug Discovery & Development > News
MilliporeSigma opens China's first end-to-end biodevelopment center in Shanghai
MilliporeSigma announced the opening of its first BioReliance end-to-end biodevelopment center in the Asia Pacific (APAC) region.
Drug Research > Drug Discovery & Development > News
GSK, AstraZeneca, Labcyte form alliance to develop acoustic mass spectrometry
Labcyte announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from Labcyte with Mass Spectrometry (MS) for use in high throughput small molecule screening and other drug discovery applications.
Drug Research > Drug Discovery & Development > News
Ultragenyx proposes to acquire Dimension Therapeutics
By PBR Staff Writer
Ultragenyx Pharmaceutical has made a proposal to acquire all of the outstanding shares of common stock of Dimension Therapeutics for $5.50 per share, or approximately $138m, in cash at close to be effectuated via a tender offer.
Drug Research > Drug Discovery & Development > News
Mustang Bio announces expansion of CAR T pipeline into CD20-directed immunotherapies
Mustang Bio, a Fortress Biotech company, has announced the expansion of its pipeline of CAR T therapies into CD20-directed immunotherapies.
Drug Research > Drug Discovery & Development > News
BMS to use Halozyme’s Enhanze technology to develop immuno-oncology medicines
By PBR Staff Writer
Bristol-Myers Squibb (BMS) has partnered with Halozyme Therapeutics for the development of immuno-oncology medicines.
Drug Research > Drug Discovery & Development > News
Berkeley Lights, Bayer partner for cell line development and antibody discovery
Berkeley Lights (BLI), a company dedicated to bringing to market transformational platforms for bio-pharmaceutical processes, has announced a strategic project with Bayer, focused on the innovation and acceleration of cell line development, antibody discovery, and research.
Drug Research > Drug Discovery & Development > News
226-240 of 4721 results